Chang Hung, Shih Lee-Yung
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Chang Gung Med J. 2008 Sep-Oct;31(5):510-4.
Imatinib is a selective tyrosine kinase inhibitor which acts on breakpoint cluster region-Abelson fusion gene (BCR-ABL) positive leukemia including all phases of chronic myeloid leukemia and acute lymphoblastic leukemia. It may induce rapid apoptosis and subsequent tumor lysis syndrome. Only 3 cases of imatinib-induced tumor lysis syndrome have been reported. We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib. Experience in the current case suggests that preventive measures for tumor lysis syndrome, including allopurinol and hydration, should be taken for patients with high leukemia burden who receive imatinib therapy, and parameters of tumor lysis should be monitored in the early phase of therapy.
伊马替尼是一种选择性酪氨酸激酶抑制剂，作用于断裂点簇集区-阿贝尔森融合基因（BCR-ABL）阳性白血病，包括慢性髓性白血病各期及急性淋巴细胞白血病。它可能诱导快速凋亡及随后的肿瘤溶解综合征。仅报道过3例伊马替尼诱导的肿瘤溶解综合征。我们在此描述了另一例BCR-ABL（ela2）阳性急性淋巴细胞白血病患者，在接受伊马替尼治疗10天后发生了肿瘤溶解综合征。本例的经验提示，对于接受伊马替尼治疗、白血病负荷高的患者，应采取包括别嘌醇和水化在内的肿瘤溶解综合征预防措施，并在治疗早期监测肿瘤溶解参数。
